889 reports of this reaction
7.7% of all CABOTEGRAVIR reports
#3 most reported adverse reaction
INJECTION SITE PAIN is the #3 most commonly reported adverse reaction for CABOTEGRAVIR, manufactured by ViiV Healthcare Company. There are 889 FDA adverse event reports linking CABOTEGRAVIR to INJECTION SITE PAIN. This represents approximately 7.7% of all 11,616 adverse event reports for this drug.
Patients taking CABOTEGRAVIR who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among CABOTEGRAVIR users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for CABOTEGRAVIR:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 889 FDA reports for CABOTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 7.7% of all adverse event reports for CABOTEGRAVIR, making it one of the most commonly reported side effect.
If you experience injection site pain while taking CABOTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.